What are the differences between the old and new guidelines for the treatment of ANCA-associated kidney vasculitis?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 21, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Key Differences Between Old and New Guidelines for ANCA-Associated Kidney Vasculitis

The most transformative changes from the 2016 EULAR/ERA-EDTA guidelines to the 2024 KDIGO guidelines center on dramatically reduced glucocorticoid dosing, the introduction of avacopan as a steroid-sparing agent, more restrictive use of plasma exchange, and extended maintenance therapy duration based on relapse risk stratification.

Major Therapeutic Shifts

1. Glucocorticoid Dosing: Radical Reduction

The 2024 KDIGO guidelines 1 implement the reduced-dose PEXIVAS regimen, which represents a fundamental departure from older protocols:

  • Week 1 dosing: 50-75 mg (weight-based) versus traditional high-dose protocols
  • Rapid taper: Down to 5 mg by week 16-20, maintained at 5 mg through week 52
  • Critical difference: This is approximately 50% less cumulative steroid exposure than older guidelines

The 2016 EULAR guidelines 2 did not specify such aggressive steroid reduction, representing a major quality-of-life improvement given steroid toxicity is a primary driver of morbidity.

2. Avacopan: New Steroid-Sparing Option

The 2024 guidelines introduce avacopan (C5a receptor antagonist) as an alternative to glucocorticoids 1:

  • Dosing: 30 mg twice daily in combination with rituximab or cyclophosphamide
  • Target population: Patients at high risk of glucocorticoid toxicity or with lower GFR (who may benefit from greater GFR recovery)
  • Duration: Used throughout the 52-week induction/early maintenance period

This option was completely absent from 2016 guidelines 2, representing a paradigm shift toward complement-targeted therapy.

3. Plasma Exchange: More Restrictive Indications

The threshold for plasma exchange has been raised significantly:

  • 2016 EULAR 2: Recommended for serum creatinine ≥500 µmol/L (5.7 mg/dL)
  • 2024 KDIGO 1: Consider for SCr >3.4 mg/dL (>300 µmol/L), dialysis-requiring patients, or rapidly increasing SCr

The newer guidelines reflect PEXIVAS trial data showing no mortality or ESKD benefit from routine plasma exchange, making its use more selective rather than standard practice for severe renal involvement.

4. Maintenance Therapy Duration: Extended and Risk-Stratified

2016 EULAR 2: Minimum 24 months after remission induction

2024 KDIGO 1: 18 months to 4 years based on relapse risk factors:

  • High-risk features: PR3-ANCA positivity, persistent ANCA positivity, upper respiratory tract involvement, prior relapse
  • Extended protocols: Azathioprine can be continued up to 4 years with dose reduction after 18-24 months (1.5-2 mg/kg/d initially, then 1 mg/kg/d)

This represents a more nuanced, individualized approach absent from older guidelines.

5. Rituximab Positioning: From Alternative to Preferred

While both guidelines endorse rituximab, the 2024 KDIGO guidelines 1 provide more explicit guidance:

  • Severe renal disease (SCr >4 mg/dL): Consider combination of rituximab with 2 pulses of IV cyclophosphamide
  • Maintenance after rituximab induction: Most patients should receive maintenance therapy (not just observation)
  • Dosing protocols: Two specific regimens detailed (MAINRITSAN vs. RITAZAREM schemes)

The 2016 guidelines 2 positioned rituximab and cyclophosphamide as equal alternatives without this level of algorithmic specificity.

6. Mycophenolate Mofetil: Expanded Role

2024 KDIGO 1: MMF explicitly included for induction therapy (2000-3000 mg/d) and as maintenance alternative

2016 EULAR 2: MMF mentioned only for non-organ-threatening disease with Grade C evidence

This reflects accumulating evidence supporting MMF's efficacy, particularly in resource-limited settings or when rituximab/cyclophosphamide are contraindicated.

Critical Practice Changes

Induction Therapy Algorithm

The 2024 approach is more algorithmic:

  • Rituximab preferred for: PR3-ANCA, relapsing disease, childbearing potential, malignancy history
  • Cyclophosphamide preferred for: Severe GN (SCr >4 mg/dL), immediately life-threatening disease
  • Combination rituximab + cyclophosphamide: For most severe presentations

ANCA Monitoring

Both guidelines agree: Do NOT use ANCA levels to guide treatment changes 2, 1

However, 2024 guidelines 1 add nuance: ANCA persistence/rise may predict relapse and should inform maintenance duration decisions, though not trigger treatment escalation alone.

Common Pitfalls to Avoid

  1. Do not delay treatment for biopsy in ANCA-positive patients with compatible clinical presentation and rapidly progressive disease 1

  2. Do not use traditional high-dose steroid protocols - the reduced PEXIVAS regimen is now standard of care 1

  3. Do not routinely use plasma exchange for all severe renal AAV - reserve for SCr >3.4 mg/dL or dialysis-dependent patients 1

  4. Do not stop maintenance therapy at 18 months in high-risk patients (PR3-ANCA, prior relapse) - extend to 4 years 1

  5. Do not use methotrexate for maintenance if GFR <60 mL/min/1.73 m² 1

Bottom Line

The evolution from 2016 to 2024 represents a shift toward precision medicine: lower steroid burden, complement-targeted therapy, risk-stratified maintenance duration, and more selective use of plasma exchange. These changes prioritize long-term quality of life while maintaining disease control, reflecting maturation from empiric immunosuppression to mechanistically-informed treatment strategies.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.